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Background: Ticagrelor was superior to clopidogrel in the PLATO trial. Outcomes in patients with non-ST-elevation acute coronary syndrome (NSTE-
ACS) have not been explored.
methods: We evaluated the primary endpoint (cardiovascular (CV) death, myocardial infarction (MI), stroke), its components and bleeding events 
in NSTE-ACS patients, including those medically managed, according to randomized treatment.
results: In 11,080 NSTE-ACS patients defined at randomization, baseline characteristics were similar between randomized groups: age (64 
years) diabetes (28%), previous MI (25%), previous stroke (4%), positive troponin I (81%). During the index hospitalization 73% had angiography 
and 47% PCI. The ticagrelor group had a significantly lower incidence of all ischemic outcomes including all-cause mortality. Major bleeding was 
similar. During initial hospitalization, 5020 and 4856 patients were uneventful for ischemic and bleeding events respectively and did not undergo 
revascularization. After multivariable adjustment, primary outcome was consistently reduced in medically managed patients, HR (95% CI)= 0.81 
(0.66, 0.98), p=0.029 with similar major bleeding risk, HR (95% CI)= 1.11 (0.88, 1.40), p=0.39.
conclusions: In the PLATO trial ticagrelor compared with clopidogrel consistently reduced the primary end-point and its components CV death and 
MI, without a difference in overall major bleeding, in patients with an entry diagnosis of NSTE-ACS, including in-hospital medically managed.
Outcomes in patients with NSTE-ACS in the PLATO trial.
Ticagrelor, % (N) (n=5581) Clopidogrel, % (N) (n=5499) HR (95% CI) p value
CV death/MI (excluding silent)/Stroke 10.0 (533) 12.3 (630)
0.83 (0.74, 
0.93)
0.001
CV death 3.7 (194) 4.9 (247)
0.77 (0.64, 
0.93)
0.007
All cause death 4.3 (224) 5.8 (290)
0.76 (0.64, 
0.90)
0.002
MI (excluding silent) 6.6 (345) 7.7 (392)
0.86 (0.74, 
0.99)
0.042
PLATO major bleeding 13.4 (660) 12.6 (618)
1.07 (0.95, 
1.19)
0.26
- CABG related 9.0 (449) 9.3 (463)
0.96 (0.84, 
1.10)
0.56
- Non CABG related 4.8 (225) 3.8 (176)
1.28 (1.05, 
1.56)
0.014
Life Threatening or Fatal Bleeding 6.6 (331) 6.5 (315)
1.05 (0.90, 
1.22)
0.56
